FDA clears Zoll hospital defibrillators

Zoll Medical, a manufacturer of resuscitation devices and related software products, has received 510(k) clearance from the FDA to market and sell its new Zoll R Series BLS and R Series Plus defibrillators. 

The Chelmsford, Mass.-based company said its new R Series BLS and R Series Plus are designed to extend defibrillation to hospital departments with solutions for resuscitation. The R Series BLS is an AED that becomes a life-support device. The R Series Plus, which has both AED and ALS capabilities, also has networking capabilities and See-Thru CPR, which allows the professional rescuer to view a patient’s underlying cardiac rhythm during resuscitation efforts without the need to stop compressions. The models provide the Real CPR Help feature that provides feedback on the rate and depth of chest compressions. Both the BLS and Plus models have CE Mark and are available in English, French, Italian, German, Danish and Finnish.

Based on WiFi technology, the R Series sends a status of its state of readiness at a programmed time. Early notification maximizes patient safety by letting the clinician intervene before the defibrillator is needed for a code, Zoll said.

Around the web

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services.